T Cell News and Research

Latest T Cell News and Research

New therapeutic target could boost CAR T-cell therapy success in solid tumors

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, "TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids".

10 Jan 2025

Single-dose malaria vaccine offers unprecedented 90% protection

Results from the malaria vaccine trial indicate that GA2 immunization provides significant protection, paving the way for more effective vaccination strategies.

8 Jan 2025

Decades of research push cytomegalovirus vaccine closer to reality

Researchers review decades of progress in human cytomegalovirus (HCMV) vaccine development, emphasizing challenges, innovative platforms, and the critical need for effective prevention strategies.

6 Jan 2025

Topical immunotherapy clears precancerous skin lesions and reduces cancer risk

Calcipotriol-plus–5-FU therapy activates immune pathways, offering long-lasting protection against squamous cell carcinoma by targeting precancerous lesions.

6 Jan 2025

Predicting H5N1 disease severity based on T cell responses

New research led by scientists at La Jolla Institute for Immunology (LJI) suggests that many people already have immune cells on "stand by" to fight the H5N1 virus, also known as highly pathogenic avian influenza.

2 Jan 2025

Specialized bone marrow niches reveal secrets of immune tolerance

Researchers have uncovered a hierarchical structure of immune-privileged stem cells in bone marrow niches, revealing their regenerative potential and therapeutic relevance.

2 Jan 2025

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

Kaempferol boosts immune tolerance and fights allergies

Kaempferol's role in Treg development is linked to Aldh1a2 activation in dendritic cells, highlighting its potential in suppressing inflammation and allergies.

19 Dec 2024

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

Flavonoid kaempferol could offer natural relief for food allergies

Allergic diseases such as asthma, atopic dermatitis, and food allergies have been increasing in frequency over the last few years.

16 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

New insights into accelerated aging in young sickle cell patients

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 21 on November 14, 2024, entitled, "Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression."

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

New $1.4M grant supports innovative kidney cancer treatment strategy

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

10 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024